Feedback Share Discussion Threads

[lr2] 12/8/2019 11:13

"The New Ordinary Shares will represent 30.78% of the issued share capital of the Company as enlarged by the Fundraise."

My post #2199
BUT the Placing Price represents a true discount of approximately 31.4% to the closing mid-market price of 1.75 pence per Ordinary Share on the day before the placing was leaked.

30.78% vs. 31.4% - close enough. Don't tell me the markets didn't know about the leak. Damned impressive coincidence if they didn't.

[davydoo] 12/8/2019 10:59

An 80% net profit margin in 1 year for a health tech company having only sold in to one market, would probably be valued at a PE of 100 not 10

Although it would probably be bought out before it ever made it to that

[bobd29] 12/8/2019 10:51

Thanks lr2. IF I assume with all other income/costs a PROFIT of say 4£m in the next year and a PER of just 10x then the share price should be appx 8p? A profit ought to mean an end to fundraising at least for a while also. Further ahead maybe Bleepa international expansion and rollout of TexRAD clinical? End of 2020 may at last reward lths (if any have stayed the distance). Just musing....dyor.

[lr2] 12/8/2019 10:19

Morning Bob,
In the placing document it states, "In the UK, across NHS hospital, community and primary care settings, there are approximately 150,000 doctors in total and over 320,000 nurses and midwives."

So a potential 470,000 users at first glance. However take out GP's and nursing staff working outside hospitals, say 25%, then practical UK market for Bleepa is down to around 352,500 and many of them work at multiple hospitals.

I'd estimate true market is around 275,000 individuals.

15% take up would be 41,250.

41,250 individuals at £10 a month is a yearly revenue stream of £4,950,000.

Round it up to £5 million for ease of use.

Looks like that will cover company costs and leave some money in the bank but nothing too exciting.

[bobd29] 12/8/2019 10:06

Morning lr2, assuming these figs verify and let’s also assume say a 15% takeup what does that give in likely user numbers? This just for the UK, and ignoring any add-ons from Cadran sales etc, will give some idea of Bleepa income to FDBK. Then we can see whether the fundraise was beneficial to shareholders.still cannot see why it wasn’t delayed a few weeks for a higher price though. Shady doings all round on this one?

[lr2] 12/8/2019 09:36

The Placing is NOT being underwritten. Hence just £100k (apply sarcasm here) as cost of placing. Suggest Peterhouse and Stanford Capital earn their money by finding out who leaked the placing.

The Placing Price represents a discount of approximately 14.3% to the closing mid-market price of 1.4 pence per Ordinary Share on 9 August 2019.

BUT the Placing Price represents a true discount of approximately 31.4% to the closing mid-market price of 1.75 pence per Ordinary Share on the day before the placing was leaked.

It is proposed to market BleepaTM using a SaaS model and charging in the order of £10 per month per user, with a 12-month minimum contract and a 3 month cancellation period.

First 16,667 medical staff signing up to Bleepa for 12 months will cover the £2 mil raised by this placing.

First 833 medical staff signing up to Bleepa for 12 months will cover Peterhouse and Stanford Capital's costs.

[dave4545] 12/8/2019 09:33

Herb

I've seen your trades when you mention them now and again and they are never large.

You do not do subtle very well.

[lr2] 12/8/2019 09:21

Re post #2193.

They don't have the money yet. The placing is not being underwritten and they only have a confirmed take up for 57,700,000 shares (£692,400) at present.

[herb clark] 12/8/2019 09:19

I have a large holding actually

[dave4545] 12/8/2019 09:18

"surprised this isn,t down more" (I've not bought so I'll deramp it hoping somebody sells so I can buy cheaper"

"these look like a good buy"

(I've bought in now so I can now ramp it)

Where do they come from, has NTTG apologised for yet again more false rumours this time about a 1.8p placing with his entropick twitter account ?

[herb clark] 12/8/2019 09:16

These look like a good buy

[davydoo] 12/8/2019 09:14

£2,000,000 of investors faith in Bleepa, let's see it put to work

[lr2] 12/8/2019 08:28

Very true Duc. Real cost of placing much higher than indicated.

[ducatiman] 12/8/2019 08:26

The placing could have been much higher but it was leaked in order to get the price lower, very shoddy!

[herb clark] 12/8/2019 08:22

Surprised this isn't down more

[dplewis1] 12/8/2019 08:18

Tenner a month seems way too steep if you ask me.

[lalji027] 12/8/2019 08:08

They should offer a discount or promotion at the start, id say sumthing like first 1000 users get free for 1 yr, this would help self promoting and word of mouth.

or 6mnths free, this way many would trial it for their use and if they like and fits their purpose, then they would subscribe and pay

[newtothisgame3] 12/8/2019 07:52

#FDBK @BleepaMe Bleepa will be available under a SaaS model at a cost of around £10 per month per user

[ducatiman] 12/8/2019 07:38

1.2p that's a result for the insts. Co' has been truly legged over!

[dplewis1] 12/8/2019 07:04

Oh well, so it was 1.2p after all..

[lr2] 11/8/2019 20:45

Simon Eccles - Chief Clinical Information Officer for Health and Care. Deputy CEO NHSX.